Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Asset Writedowns and Impairment (2016 - 2025)

IGC Pharma has reported Asset Writedowns and Impairment over the past 11 years, most recently at $152000.0 for Q1 2025.

  • Quarterly Asset Writedowns and Impairment rose 104.66% to $152000.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was -$3.0 million through Mar 2025, up 4.84% year-over-year, with the annual reading at $152000.0 for FY2025, 63.44% up from the prior year.
  • Asset Writedowns and Impairment was $152000.0 for Q1 2025 at IGC Pharma, up from -$3.3 million in the prior quarter.
  • Over five years, Asset Writedowns and Impairment peaked at $152000.0 in Q1 2025 and troughed at -$3.3 million in Q1 2024.
  • The 5-year median for Asset Writedowns and Impairment is $37000.0 (2021), against an average of -$767000.0.
  • Year-over-year, Asset Writedowns and Impairment surged 114.24% in 2023 and then plummeted 2691.27% in 2024.
  • A 5-year view of Asset Writedowns and Impairment shows it stood at $37000.0 in 2021, then crashed by 2491.89% to -$885000.0 in 2022, then surged by 114.24% to $126000.0 in 2023, then plummeted by 2691.27% to -$3.3 million in 2024, then surged by 104.66% to $152000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Asset Writedowns and Impairment are $152000.0 (Q1 2025), -$3.3 million (Q1 2024), and $126000.0 (Q1 2023).